• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

rs3212986 A/C基因多态性与胃癌患者的化疗治疗结果无关:来自中国人群11篇出版物的证据。

rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.

作者信息

Tang Weiwei, Wang Hanjin, Wang Yuemei, Wang Xiaowei

机构信息

Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Department of Operation Anesthesiology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, People's Republic of China.

出版信息

Onco Targets Ther. 2017 Dec 20;11:1-8. doi: 10.2147/OTT.S148214. eCollection 2018.

DOI:10.2147/OTT.S148214
PMID:29302191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5741989/
Abstract

BACKGROUND

A number of studies have investigated the roles of excision repair cross-complementation group 1 () gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC.

METHODS

PubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC. A fixed-effect or random-effect model was used to calculate the pooled odds ratios (ORs) based on the results from the heterogeneity tests.

RESULTS

The result revealed that there was no significant association between the rs3212986 A/C polymorphism and response to chemotherapy in GC under comparison models (AA + CA versus CC, OR 0.95, =0.80, AA versus CA, OR 0.85, =0.55, AA versus CC, OR 0.74, =0.47). Further identification suggested that rs3212986 A/C polymorphisms were not linked with the overall survival of GC (AA + CA versus CC, OR 1.09, =0.52, AA versus CA, OR 1.05, =0.85, AA versus CC, OR 1.43, =0.23).

CONCLUSION

Our meta-analysis indicated that the rs3212986 A/C polymorphism was not associated with response to chemotherapy or overall survival time in GC. Well-designed studies with larger sample sizes and more ethnic groups should be performed to further validate our results.

摘要

背景

多项研究探讨了切除修复交叉互补基因1()rs3212986多态性作为胃癌(GC)潜在生物标志物的作用。然而,结果并不一致。在此,我们进行了一项荟萃分析,以探讨rs3212986多态性与GC化疗反应及临床结局之间的关系。

方法

检索截至2017年7月28日的PubMed、Embase和Web of Science数据库,查找关于rs3212986 A/C多态性与GC化疗反应及总生存时间相关性的研究。根据异质性检验结果,采用固定效应或随机效应模型计算合并比值比(OR)。

结果

结果显示,在比较模型下,rs3212986 A/C多态性与GC化疗反应之间无显著关联(AA + CA与CC相比,OR 0.95,=0.80;AA与CA相比,OR 0.85,=0.55;AA与CC相比,OR 0.74,=0.47)。进一步分析表明,rs3212986 A/C多态性与GC总生存无关(AA + CA与CC相比,OR 1.09,=0.52;AA与CA相比,OR 1.05,=0.85;AA与CC相比,OR 1.43,=0.23)。

结论

我们的荟萃分析表明,rs3212986 A/C多态性与GC化疗反应或总生存时间无关。应开展设计更完善、样本量更大且涉及更多种族群体的研究,以进一步验证我们的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/bc66f7e8a78b/ott-11-001Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/96e121ede3ec/ott-11-001Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/dbaa5d0d74c2/ott-11-001Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/6673d0b8fd82/ott-11-001Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/8c15476c15d0/ott-11-001Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/bc66f7e8a78b/ott-11-001Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/96e121ede3ec/ott-11-001Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/dbaa5d0d74c2/ott-11-001Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/6673d0b8fd82/ott-11-001Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/8c15476c15d0/ott-11-001Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2912/5741989/bc66f7e8a78b/ott-11-001Fig5.jpg

相似文献

1
rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.rs3212986 A/C基因多态性与胃癌患者的化疗治疗结果无关:来自中国人群11篇出版物的证据。
Onco Targets Ther. 2017 Dec 20;11:1-8. doi: 10.2147/OTT.S148214. eCollection 2018.
2
Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.ERCC1和ERCC2基因多态性对接受铂类化疗的胃癌患者的预后价值
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15065-71. eCollection 2015.
3
Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma.ERCC1基因rs3212986位点及ERCC2基因rs13181位点多态性与胶质瘤风险的关联
Pak J Med Sci. 2014 Nov-Dec;30(6):1409-14. doi: 10.12669/pjms.306.5221.
4
Systematic review on the association between ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms and glioma risk.关于ERCC1 rs3212986和ERCC2 rs13181基因多态性与胶质瘤风险之间关联的系统评价。
Genet Mol Res. 2015 Mar 31;14(1):2868-75. doi: 10.4238/2015.March.31.17.
5
Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.ERCC基因常见多态性与胶质瘤风险的关联:15项研究的荟萃分析
Medicine (Baltimore). 2017 May;96(20):e6832. doi: 10.1097/MD.0000000000006832.
6
polymorphism and its expression associated with ischemic stroke in Chinese population.中国人群中与缺血性中风相关的多态性及其表达
Front Neurol. 2023 Jan 12;13:998428. doi: 10.3389/fneur.2022.998428. eCollection 2022.
7
Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis.核苷酸切除修复基因 ERCC1 多态性与癌症易感性有关:荟萃分析。
Mutagenesis. 2012 Jan;27(1):67-76. doi: 10.1093/mutage/ger062. Epub 2011 Oct 13.
8
Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.基于病例对照研究的ERCC1基因多态性(rs3212986和rs11615)与头颈癌风险的关联
Clin Transl Oncol. 2015 Sep;17(9):710-9. doi: 10.1007/s12094-015-1298-7. Epub 2015 May 29.
9
Association of excision repair cross-complimentary group 1 gene polymorphisms with breast and ovarian cancer susceptibility.切除修复交叉互补基因 1 多态性与乳腺癌和卵巢癌易感性的关联。
J Cell Biochem. 2019 Sep;120(9):15635-15647. doi: 10.1002/jcb.28830. Epub 2019 May 12.
10
Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis.ERCC1基因多态性与肺癌易感性的关联研究:一项系统评价和荟萃分析。
PLoS One. 2014 May 19;9(5):e97616. doi: 10.1371/journal.pone.0097616. eCollection 2014.

引用本文的文献

1
AI-Powered Insights into Drug Resistance in Gastric Cancer: A Path Toward Precision Therapy.人工智能助力洞察胃癌耐药性:精准治疗之路
Iran J Pharm Res. 2025 May 25;24(1):e159954. doi: 10.5812/ijpr-159954. eCollection 2025 Jan-Dec.
2
Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.胃腺癌耐药机制的分子基础
Cancers (Basel). 2020 Jul 30;12(8):2116. doi: 10.3390/cancers12082116.

本文引用的文献

1
Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.荟萃分析表明,ERCC1基因多态性可预测骨肉瘤的预后。
Oncotarget. 2017 Jul 19;8(37):62769-62779. doi: 10.18632/oncotarget.19370. eCollection 2017 Sep 22.
2
Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.遗传多态性与非小细胞肺癌铂类化疗治疗结局:基于遗传流行病学研究的荟萃分析。
Sci Rep. 2017 Jul 17;7(1):5593. doi: 10.1038/s41598-017-05642-0.
3
Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.
ERCC基因常见多态性与胶质瘤风险的关联:15项研究的荟萃分析
Medicine (Baltimore). 2017 May;96(20):e6832. doi: 10.1097/MD.0000000000006832.
4
Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.参与核苷酸切除修复途径的ERCC1和ERCC2基因的遗传变异性会影响胃癌的治疗结果。
Genet Mol Res. 2016 Apr 26;15(2):gmr7384. doi: 10.4238/gmr.15027384.
5
Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.ERCC1和ERCC2基因多态性对接受铂类化疗的胃癌患者的预后价值
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15065-71. eCollection 2015.
6
Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.ERCC1和ERCC2的基因变异性影响胃癌的治疗结果。
Genet Mol Res. 2015 Dec 21;14(4):17529-35. doi: 10.4238/2015.December.21.25.
7
Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.核苷酸切除修复(NER)途径中ERCC1基因的遗传变异性影响胃癌的治疗结果。
Int J Clin Exp Pathol. 2015 Oct 1;8(10):13367-73. eCollection 2015.
8
Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.DNA修复机制的遗传变异性对胃癌患者化疗治疗结果的影响
Genet Mol Res. 2015 Dec 17;14(4):17228-34. doi: 10.4238/2015.December.16.22.
9
Genetic variability of DNA repair mechanisms influences treatment outcome of gastric cancer.DNA修复机制的遗传变异性影响胃癌的治疗结果。
Oncol Lett. 2015 Oct;10(4):1997-2002. doi: 10.3892/ol.2015.3510. Epub 2015 Jul 17.
10
Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.核苷酸切除修复(NER)途径中基因的遗传变异性会影响胃癌的治疗结果。
Int J Clin Exp Pathol. 2015 May 1;8(5):5563-9. eCollection 2015.